JANX011 Hits Deep B-Cell Depletion With Only Grade 1 CRS in First Human Data
JANX sits 47% above its 52-week low of $12.12.
Summary
Janux reported the first human data for JANX011, a CD19-targeted T-cell engager from its ARM platform, in 25 healthy volunteers. After a single subcutaneous dose with no step-up dosing, 3 of 5 participants at 3 mg achieved more than 90% B-cell depletion, including two below the limit of detection, and reductions persisted through Day 42. CRS was Grade 1 only — none in the 16 participants dosed at 30 to 300 µg, one of four at 1 mg and four of five at 3 mg — with no serious adverse events or dose-limiting toxicities; transient liver enzyme elevations appeared at 3 mg. This is the first clinical validation of ARM and gives Janux a second platform beyond its prostate cancer TRACTr programs. Management now plans autoimmune patient studies in immune thrombocytopenia in the first half of 2027 and rheumatoid arthritis in the second half. The company had $945.7 million in cash and investments as of the November 5 10-Q, so funding the expansion is not the near-term constraint. An investor webcast is scheduled for 8:30 a.m. ET today.
At the time of this announcement, JANX was trading at $17.85 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $12.12 to $35.34. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: BusinessWire.